Daratumumab: Durable Efficacy in Heavily Treated Multiple Myeloma
Daratumumab monotherapy demonstrated promising efficacy and a manageable safety profile in heavily pretreated patients with multiple myeloma in a pooled, post-hoc analysis of the GEN501 and SIRIUS studies....
CNP, DipACLM Nurse Practitioner, Massachusetts General Hospital
Study Reveals Need for Better Therapies in Triple-Class Exposed Multiple Myeloma
The LocoMMotion study, a multinational prospective observational trial, examined the effectiveness and safety of real-world clinical practice treatments in triple-class exposed patients with multiple myeloma who had received proteasome inhibitors,...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Elevating Myeloma Care: Daratumumab Plus Lenalidomide/Bortezomib/Dexamethasone Sets a New Standard
Advances in myeloma treatment have significantly improved patient outcomes, with the combination of lenalidomide, bortezomib, and dexamethasone (RVd) becoming a cornerstone of care....
CAR T-Cell Therapy Offers Hope for Relapsed Multiple Myeloma
Multiple myeloma (MM) impacts around 35,000 new patients annually in the United States, with over 12,000 deaths. Advances in treatments like proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies have improved...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Rare Multiple Myeloma Case in Pregnancy Successfully Managed With Treatment, Leading to Healthy Delivery
Multiple myeloma (MM) during pregnancy is rare, with only 45 cases reported between 1965 and 2020. In the presented case, a 40-year-old woman was diagnosed with oligosecretory IgG kappa MM...
Managing Multiple Myeloma: Addressing Bone Disease and Improving Treatment Options for Older Adults
Multiple myeloma (MM) is a cancer of clonal plasma cells primarily affecting older adults, with approximately 35,000 new cases annually in the United States. Advances in treatment, including immunomodulatory drugs,...
Tailoring CAR-T Therapy for Older Adults: Addressing Frailty and Improving Outcomes
CAR-T therapy has been effective in treating relapsed/refractory hematologic cancers like multiple myeloma and diffuse large B-cell lymphoma, especially in older adults. However, its use in patients aged 75 and...
